Eledon Q2 FY26 net loss widens to $31.6 million

Reuters2026/08/13 20:08

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Eledon Pharmaceuticals posted a wider Q2 2026 net loss of USD 31.6 million, or USD 0.27 per share, versus USD 11.2 million.
R&D expense fell to USD 18.2 million from USD 20.3 million, while G&A edged up to USD 4.6 million from USD 4.5 million.
Cash, cash equivalents and short-term investments slid to USD 88.8 million at June 30 from USD 133.3 million at Dec. 31.
Net loss included a USD 9.6 million non-cash warrant fair-value loss versus a USD 12.3 million non-cash gain a year earlier.
David-Alexandre C. Gros said a successful FDA end-of-Phase 2 meeting keeps a global Phase 3 kidney transplant trial on track for late 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eledon Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608131605PRIMZONEFULLFEED9809869) on August 13, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Eledon Q2 FY26 net loss widens to $31.6 million

You may also like

Crypto prices